7 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
Royalty Assets 5 Our royalty assets, composed of widely used respiratory therapies commercialized by GSK, have produced durable, resilient revenues … driven by resilient cash flows from our core GSK royalties portfolio and robust revenue growth across our commercial products marketed by IST
8-K
EX-99.1
INVA
Innoviva Inc
8 May 24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
4:44pm
financial results continue to demonstrate the successful transformation for Innoviva. We had a strong performance driven by resilient cash flows from
8-K
EX-99.1
INVA
Innoviva Inc
13 Dec 21
Corporate Presentation December 2021
4:39pm
while we build out the next generation of high impact products Sizeable and differentiated Resilient and durable Diversified and growing Differentiated
8-K
EX-99.1
INVA
Innoviva Inc
14 Sep 22
Regulation FD Disclosure
5:22pm
Sizeable and differentiated Resilient anddurable Diversifiedand established Differentiated respiratory portfolio with over $2B 2021 sales (for Breo and Anoro
8-K
EX-99.1
INVA
Innoviva Inc
7 Apr 22
Regulation FD Disclosure
5:09pm
the next generation of high impact products Sizeable and differentiated Resilient anddurable Diversifiedand growing Differentiated respiratory
8-K
EX-99.1
wmkh30et4bd
24 May 23
Corporate Presentation May 2023
5:18pm
- Prev
- 1
- Next